102 related articles for article (PubMed ID: 38781933)
1. Gender differences in lung neuroendocrine tumors: a single-center experience.
Liccardi A; Colao A; Modica R
Neuroendocrinology; 2024 May; ():. PubMed ID: 38781933
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
3. Prognostic significance of laterality in lung neuroendocrine tumors.
La Salvia A; Persano I; Siciliani A; Verrico M; Bassi M; Modica R; Audisio A; Zanata I; Trabalza Marinucci B; Trevisi E; Puliani G; Rinzivillo M; Parlagreco E; Baldelli R; Feola T; Sesti F; Razzore P; Mazzilli R; Mancini M; Panzuto F; Volante M; Giannetta E; Romero C; Appetecchia M; Isidori A; Venuta F; Ambrosio MR; Zatelli MC; Ibrahim M; Colao A; Brizzi MP; García-Carbonero R; Faggiano A
Endocrine; 2022 Jun; 76(3):733-746. PubMed ID: 35301675
[TBL] [Abstract][Full Text] [Related]
4. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
5. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
8. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
[TBL] [Abstract][Full Text] [Related]
9. High Metabolic Tumour Volume on 18-Fluorodeoxyglucose Positron Emission Tomography Predicts Poor Survival from Neuroendocrine Neoplasms.
Chan DL; Bernard EJ; Schembri G; Roach PJ; Johnson M; Pavlakis N; Clarke S; Bailey DL
Neuroendocrinology; 2020; 110(11-12):950-958. PubMed ID: 31711058
[TBL] [Abstract][Full Text] [Related]
10. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
11. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
[TBL] [Abstract][Full Text] [Related]
12. [Pulmonary carcinoid: analysis of a single institutional experience and prognostic factors].
Correia Sda S; Pinto C; Bernardo J
Acta Med Port; 2014; 27(6):749-54. PubMed ID: 25641291
[TBL] [Abstract][Full Text] [Related]
13. Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs.
Lenotti E; Alberti A; Spada F; Amoroso V; Maisonneuve P; Grisanti S; Baggi A; Bianchi S; Fazio N; Berruti A
Front Endocrinol (Lausanne); 2021; 12():669484. PubMed ID: 33986731
[TBL] [Abstract][Full Text] [Related]
14. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
[TBL] [Abstract][Full Text] [Related]
15. Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.
Chan DL; Rodriguez-Freixinos V; Doherty M; Wasson K; Iscoe N; Raskin W; Hallet J; Myrehaug S; Law C; Thawer A; Nguyen K; Singh S
Eur J Cancer; 2022 Jul; 169():74-81. PubMed ID: 35504244
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
[TBL] [Abstract][Full Text] [Related]
18. Gender-related differences in patients with carcinoid syndrome: new insights from an Italian multicenter cohort study.
Ruggeri RM; Altieri B; Razzore P; Retta F; Sperti E; Scotto G; Brizzi MP; Zumstein L; Pia A; Lania A; Lavezzi E; Nappo G; Laffi A; Albertelli M; Boschetti M; Hasballa I; Veresani A; Prinzi N; Pusceddu S; Oldani S; Nichetti F; Modica R; Minotta R; Liccardi A; Cannavale G; Grossrubatscher EM; Tarsitano MG; Zamponi V; Zatelli MC; Zanata I; Mazzilli R; Appetecchia M; Davì MV; Guarnotta V; Giannetta E; La Salvia A; Fanciulli G; Malandrino P; Isidori AM; Colao A; Faggiano A;
J Endocrinol Invest; 2024 Apr; 47(4):959-971. PubMed ID: 37837555
[TBL] [Abstract][Full Text] [Related]
19. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
[TBL] [Abstract][Full Text] [Related]
20. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH): Prevalence, clinicopathological characteristics and survival outcome in a cohort of 311 patients with well-differentiated lung neuroendocrine tumours.
Hayes AR; Luong TV; Banks J; Shah H; Watkins J; Lim E; Patel A; Grossman AB; Navalkissoor S; Krell D; Caplin ME
J Neuroendocrinol; 2022 Oct; 34(10):e13184. PubMed ID: 36121922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
